Teske Nico, Teske Nina C, Niyazi Maximilian, Belka Claus, Thon Niklas, Tonn Joerg-Christian, Forbrig Robert, Karschnia Philipp
Department of Neurosurgery, Munich University Hospital, LMU Munich, 81377 Munich, Germany.
German Cancer Consortium (DKTK), Partner Site Munich, 80336 Munich, Germany.
Cancers (Basel). 2023 Mar 14;15(6):1745. doi: 10.3390/cancers15061745.
In newly diagnosed IDH-wildtype glioblastoma, the frequency and prognostic relevance of tumor regrowth between resection and the initiation of adjuvant radiochemotherapy are unclear. In this retrospective single-center study we included 64 consecutive cases, for whom magnetic resonance imaging (MRI) was available for both the volumetric assessment of the extent of resection immediately after surgery as well as the volumetric target delineation before the initiation of adjuvant radiochemotherapy (time interval: 15.5 ± 1.9 days). Overall, a median new contrast-enhancement volume was seen in 21/64 individuals (33%, 1.5 ± 1.5 cm), and new non-contrast lesion volume in 18/64 patients (28%, 5.0 ± 2.3 cm). A multidisciplinary in-depth review revealed that new contrast-enhancement was either due to (I) the progression of contrast-enhancing tumor remnants in 6/21 patients or (II) distant contrast-enhancing foci or breakdown of the blood-brain barrier in previously non-contrast-enhancing tumor remnants in 5/21 patients, whereas it was unspecific or due to ischemia in 10/21 patients. For non-contrast-enhancing lesions, three of eighteen had progression of non-contrast-enhancing tumor remnants and fifteen of eighteen had unspecific changes or changes due to ischemia. There was no significant association between findings consistent with tumor regrowth and a less favorable outcome (overall survival: 14 vs. 19 months; = 0.423). These findings support the rationale that analysis of the postsurgical remaining tumor-volume for prognostic stratification should be carried out on immediate postoperative MRI (<72 h), as unspecific changes are common. However, tumor regrowth including distant foci may occur in a subset of IDH-wildtype glioblastoma patients diagnosed per WHO 2021 classification. Thus, MRI imaging prior to radiotherapy should be obtained to adjust radiotherapy planning accordingly.
在新诊断的异柠檬酸脱氢酶(IDH)野生型胶质母细胞瘤中,手术切除与辅助放化疗开始之间肿瘤再生长的频率及预后相关性尚不清楚。在这项回顾性单中心研究中,我们纳入了64例连续病例,这些病例术后即刻有用于评估切除范围的磁共振成像(MRI)容积数据,且在辅助放化疗开始前有用于容积靶区勾画的MRI数据(时间间隔:15.5±1.9天)。总体而言,64例中有21例(33%,1.5±1.5 cm)出现新的强化灶容积中位数,64例中有18例(28%,5.0±2.3 cm)出现新的非强化灶容积。多学科深入评估显示,新的强化灶要么是由于(I)6/21例患者中强化肿瘤残留进展,要么是由于(II)5/21例患者中先前非强化肿瘤残留出现远处强化灶或血脑屏障破坏,而10/21例患者的强化灶是非特异性的或由缺血导致。对于非强化灶,18例中有3例出现非强化肿瘤残留进展,18例中有15例出现非特异性改变或缺血性改变。与肿瘤再生长一致的发现与较差预后之间无显著关联(总生存期:14个月对19个月;P=0.423)。这些发现支持这样的理论依据,即由于非特异性改变很常见,术后预后分层的手术残留肿瘤体积分析应基于术后即刻MRI(<72小时)进行。然而,按照世界卫生组织2021年分类诊断的IDH野生型胶质母细胞瘤患者亚组中可能会出现包括远处病灶在内的肿瘤再生长。因此,放疗前应进行MRI成像以相应调整放疗计划。